HA particles as resourceful cancer, steroidal and antibiotic drug delivery device with sustainable and multiple drug release capability


Sahiner N., Suner S., Kurt S. B., Can M., Ayyala R. S.

JOURNAL OF MACROMOLECULAR SCIENCE PART A-PURE AND APPLIED CHEMISTRY, vol.58, no.3, pp.145-155, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 58 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1080/10601325.2020.1832518
  • Journal Name: JOURNAL OF MACROMOLECULAR SCIENCE PART A-PURE AND APPLIED CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Aerospace Database, Biotechnology Research Abstracts, CAB Abstracts, Chimica, Communication Abstracts, Compendex, Metadex, Civil Engineering Abstracts
  • Page Numbers: pp.145-155
  • Keywords: Hyaluronic acid macromolecules, multiple drug release, cancer drug, biological macromolecule derived micro, nano particles, controlled release, HYALURONIC-ACID, INJECTABLE HYDROGELS, MOLECULAR-WEIGHT, NANOPARTICLES, INTEGRIN, EFFICIENCY, SCAFFOLDS, LIPOSOMES, FEVER, CELLS
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

Hyaluronic acid (HA) particles with divinyl sulfone (DVS) crosslinking at 10% mole ratio (HA macromolecule repeating units) were prepared and demonstrated as versatile drug carriers with sustainable and long-term release capabilities for cancer drugs, corticosteroid, and antibiotics. Two different methods were chosen in drug loading process; encapsulation for cancer drugs, 5-fluorouracil (5FU), mitomycin C (MMC), and doxorubicin (Dox), and dual drug conjugation for anti-inflammatory glucocorticoid dexamethasone (Dex) and antibiotic ciprofloxacin (Cipro) drugs, respectively. It was demonstrated that HA particles prepared during drug encapsulation were attained smaller sizes with 833 +/- 46, 867 +/- 50, 728 +/- 41 nm for 5FU, MMC, and Dox, respectively. Bare and drug loaded HA particles were shown to be blood compatible with the highest hemolytic ratio of 3.1 +/- 0.12% for HA-Dex-Cipro conjugates and fairly good blood clotting index with minimum 71.7 +/- 6.0% for MMC encapsulated HA particles. Drug release studies from HA particles indicated that depending on the types of cancer drugs, it is possible to gradually release the drug in long-term up to 300 h in linear fashions with the highest release of 9.34 +/- 2.25 mg/g for 5FU. Similarly, drug conjugated HA-Dex-Cipro particles were also showed linear dual drug release up to 100 h at physiological conditions, pH 7.4 and 37.5 degrees C.